# Braveheart Bio, Inc. (BRVE)

> Source: Nexqual · https://nexqual.com/BRVE · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, Braveheart Bio, Inc. (BRVE), nexqual.com/BRVE" · informational, not investment advice.

## BRVE major shareholder filing: Schedule 13D/A, Sep 10, 2026
ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC filed a Schedule 13D/A on Sep 10, 2026, reporting up to 13.50% of the class (more than 5% owner that may seek to influence the company). Item 4, Purpose of Transaction, quoted:

> The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. …

Source: https://www.sec.gov/Archives/edgar/data/2131524/000094787126000860/0000947871-26-000860-index.htm

**Price:** USD 21.76 (-0.27% on the day) · last close of Oct 28, 2026; US market closed, not a live price. Prev close 21.82 · day 20.77–21.85 · 52w 17.86–32 · market cap $1.96B · NGM

## Key facts
- Insider open-market purchases, last ~7 months: 8 Form 4 filings, $89.2M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 45.25 (range 40–48).
- Total return with dividends: 1Y -27.0% vs S&P 500 +13.6%; 5Y -27.5% vs S&P 500 +79.8%.
- Next earnings: 2026-11-12, EPS estimate USD -0.44, revenue estimate $0K.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
Earnings yield -1.52%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
8 purchases, $89.2M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-07 | Ah Bio Fund Iv, L.P. |  | 1,100,000 | $19.8M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Forbion Growth Opportunities Fund Iii Cooperatief U.A. |  | 3,600,000 | $64.8M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Rickey James Paul | Chief Financial Officer | 27,777 | $500K | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Viehbacher Christopher | Director | 83,333 | $1.5M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Malek David I | Director | 4,166 | $75K | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Anderson Michele A. | Chief Development Officer | 1,111 | $20K | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Murdoch Travis | CEO and President | 83,333 | $1.5M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07 | Lubner David Charles | Director | 55,555 | $1000K | 18 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 45.25 (low 40, high 48).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Cantor Fitzgerald | Reiterated | Overweight | $40 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-08-06) | 5Y (from 2026-08-03) |
|---|---|---|
| Total return | -27.0% | -27.5% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | — | — |
| Volatility (annualized) | 82.9% | 83.7% |
| Max drawdown | -38.1% (Aug 2026→Oct 2026) | -37.6% (Aug 2026→Oct 2026) |

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 95.97 +0.17% · LGND (Ligand Pharmaceuticals Incorpor) USD 318.78 +2.26% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.81 +1.58% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.9 +2.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.51 +0.92% · ABVX (Abivax SA) USD 89.84 +3.26%

## More
Full page: https://nexqual.com/BRVE · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-09-08)

- "We continue to expect results from an interim analysis from LIONHEART-HCM in the second half of 2027."
- "Based on the current operating plan, Braveheart Bio estimates that its existing cash and cash equivalents, together with the net proceeds from its IPO, will be sufficient to fund its projected operating expenses and capital expenditure requirements into 2029."
- "These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of BHB-1893 and other product candidates, including the initiation, timing, progress, results and future data releases of ongoing and planned clinical trials; the timing of initiation as well as expected results from the NOBLEHEART-HCM global Phase 3 trial;"

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.44 | $0.00 | −$0.44 | $0 | 5 |
| Next quarter (ends 2026-12-31) | $-0.28 | $0.00 | −$0.28 | $0 | 5 |
| Current fiscal year (ends 2026-12-31) | $-1.78 | $0.00 | −$1.78 | $0 | 5 |
| Next fiscal year (ends 2027-12-31) | $-1.62 | $0.00 | −$1.62 | $0 | 5 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$2.51 | $2.69 | Miss −$5.20 | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-09-10 | Schedule 13D/A | ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC: 13.5% of shares, 5%+ holder that may seek to influence the company (amended) — “The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in…” | https://www.sec.gov/Archives/edgar/data/2131524/000094787126000860/0000947871-26-000860-index.htm |
| 2026-09-08 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/2131524/000162828026060905/0001628280-26-060905-index.htm |
| 2026-09-08 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/0001628280-26-060904-index.htm |
| 2026-08-18 | Schedule 13D | ORBIMED ADVISORS LLC, OrbiMed Capital GP IX LLC: 17.2% of shares, 5%+ holder that may seek to influence the company — “This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business…” | https://www.sec.gov/Archives/edgar/data/2131524/000094787126000814/0000947871-26-000814-index.htm |
| 2026-08-14 | Schedule 13D | AH Bio Fund IV, L.P., AH Equity Partners Bio IV, L.L.C.: 11.4% of shares, 5%+ holder that may seek to influence the company — “The Reporting Persons purchased the aforementioned securities for investment purposes with the aim of increasing the value of their investments and the Issuer. Subject to applicable legal requirements, one or more of the Reporting Persons may purchase additional securities of…” | https://www.sec.gov/Archives/edgar/data/2131524/000188947626000004/0001889476-26-000004-index.htm |
| 2026-08-14 | Schedule 13G | Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P.: 5.5% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/2131524/000123191926000910/0001231919-26-000910-index.htm |
| 2026-08-07 | 8-K | Bylaws or fiscal-year change | https://www.sec.gov/Archives/edgar/data/2131524/000162828026054842/0001628280-26-054842-index.htm |
| 2026-07-30 | S-1/A | Registration of new shares | https://www.sec.gov/Archives/edgar/data/2131524/000162828026050756/0001628280-26-050756-index.htm |
| 2026-07-15 | S-1 | Registration of new shares | https://www.sec.gov/Archives/edgar/data/2131524/000162828026048213/0001628280-26-048213-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.